Register for a Live Webinar on Histotripsy

HistoSonics_Romance_Billboard01_Clipped-1-1

LIVE WEBINAR

Histotripsy at Vanderbilt: Clinical Implementation & Advanced Research at an Academic Center

Launching a Histotripsy Program
Evolution of Clinical Practice: Patient selection and clinical learnings
Operational & Financial Impact
Active Research: Exploring immunomodulation
Q&A

🗓️Thursday, June 18
🕔5:00 p.m. CT (6p ET / 3p PT)
🖥️Teams Webinar

SPEAKERS

Sekhar Padmanabhan, MD, Surgical Oncologist | Vanderbilt Health

Joe Herman, MD, Medical Director | HistoSonics, Adjunct Professor | Zucker School of Medicine at Hofstra/Northwell

30Days

00Hours

01Minutes

30Seconds

CAUTION: Federal law (USA) restricts this device to sale by or on the order of a physician. The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

LIVE WEBINAR

Histotripsy at Vanderbilt: Clinical Implementation & Advanced Research at an Academic Center

🗓️Thursday, June 18🕔5:00 p.m. CT (6p ET / 3p PT)🖥️Teams Webinar

SPEAKERS

🗓️Thursday, June 18
🕔5:00 p.m. CT (6p ET / 3p PT)
🖥️Teams Webinar